Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 1.00 [0.83, 1.20] | | < 1 | | 35% | 2 studies (2/-) | 52.0 % | some concern | not evaluable | moderate | crucial | - |
progression or deaths (PFS) | 1.34 [0.81, 2.20] | | < 1 | | 91% | 2 studies (2/-) | 12.6 % | some concern | not evaluable | moderate | important | - |
DCR | 0.49 [0.30, 0.81] | | > 1 | | 64% | 2 studies (2/-) | 0.3 % | some concern | not evaluable | moderate | non important | - |
objective responses (ORR) | 0.83 [0.52, 1.33] | | > 1 | | 0% | 2 studies (2/-) | 21.9 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 1.25 [0.67, 2.33] | | < 1 | | 0% | 1 study (1/-) | 24.1 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.98 [0.68, 1.40] | | < 1 | | 0% | 1 study (1/-) | 55.1 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 1.22 [0.57, 2.59] | | < 1 | | 0% | 1 study (1/-) | 30.3 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 0.43 [0.28, 0.64] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
SAE (any grade) | 1.26 [0.86, 1.83] | | < 1 | | 0% | 1 study (1/-) | 11.9 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 0.79 [0.42, 1.50] | | < 1 | | 0% | 1 study (1/-) | 76.3 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.40 [0.29, 0.55] | | < 1 | | 12% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 0.27 [0.19, 0.39] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 0.48 [0.04, 5.36] | | < 1 | | 0% | 2 studies (2/-) | 72.1 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 0.42 [0.18, 0.98] | | < 1 | | 58% | 2 studies (2/-) | 97.8 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
Alopecia TRAE (grade 3-4) | 0.96 [0.02, 48.74] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.04 [0.00, 0.71] | | < 1 | | 0% | 1 study (1/-) | 98.5 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.19 [0.02, 1.63] | | < 1 | | 0% | 1 study (1/-) | 93.4 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.12 [0.01, 2.25] | | < 1 | | 0% | 1 study (1/-) | 92.0 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.16 [0.02, 1.31] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.48 [0.04, 5.32] | | < 1 | | 0% | 1 study (1/-) | 72.4 % | NA | not evaluable | | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.40] | | < 1 | | 0% | 1 study (1/-) | 95.7 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 1.29 [0.28, 5.84] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 0.72 [0.16, 3.25] | | < 1 | | 0% | 1 study (1/-) | 66.7 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 0.48 [0.04, 5.32] | | < 1 | | 0% | 1 study (1/-) | 72.4 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 1.93 [0.06, 57.86] | | < 1 | | 0% | 1 study (1/-) | 35.5 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.24 [0.01, 5.32] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.02 [0.00, 0.30] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.24 [0.01, 5.32] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 0.07 [0.00, 1.17] | | < 1 | | 0% | 1 study (1/-) | 96.6 % | NA | not evaluable | | non important | - |